4:17 PM
Oct 23, 2018
 |  BC Extra  |  Company News

AstraZeneca gets rights, options to basket of next-gen immuno-oncology therapies from Innate

AstraZeneca plc (LSE:AZN; NYSE:AZN) expanded its next generation immuno-oncology pipeline on Tuesday, gaining rights and options to a basket of therapies from Innate Pharma S.A. (Euronext:IPH). In return, Innate gained U.S. and European commercialization rights to hairy cell leukemia drug Lumoxiti moxetumomab pasudotox-tdfk from AZ, making it the only approved therapy in Innate's pipeline. The news sent Innate shares up €1.78 (37%) to €6.57.

On Tuesday, AZ exercised an option under its 2015 deal with Innate to gain full rights to checkpoint inhibitor monalizumab for oncology indications; the pharma also gained new options to license rights to Innate's preclinical anti-CD39 mAb IPH5201 and four yet-to-be-determined preclinical candidates.

Monalizumab is the most advanced product in the industry that targets a checkpoint receptor enriched on NK cells, a cell type that many companies are hoping to...

Read the full 649 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >